pentobarbital will reduce the level or result of etravirine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital and olopatadine intranasal each raise sedation. Prevent or Use Alternate Drug. Coadministration boosts risk of CNS despair, which can cause additive impairment of psychomotor general performance and result in daytime impairment.
pentobarbital will lessen the extent or result of prednisone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
Workout caution every time a barbiturate is administered to a nursing lady; small amounts of barbiturates are excreted in the milk
pentobarbital will lower the extent or outcome of fosphenytoin by influencing hepatic enzyme CYP2C9/ten metabolism. Use Caution/Keep track of.
pentobarbital will lower the level or outcome of solifenacin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will minimize the extent or outcome of netupitant/palonosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Keep away from or Use Alternate Drug. Netupitant is mainly metabolized by CYP3A4; keep away from use in clients who will be chronically using a solid CYP3A4 inducer
pentobarbital will reduce the level or effect of cilostazol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will decrease the level or outcome of conjugated estrogens, vaginal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will decrease the level or influence of atogepant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Intently. Advisable atogepant dosage with concomitant use of powerful or moderate CYP3A4 inducers is thirty mg or sixty mg qDay.
pentobarbital will lower the extent or impact of alfentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unknown.
Remark: Barbiturates may possibly enhance adverse effects, like respiratory melancholy, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates maximize metabolism and get more info reduce blood concentrations of TCAs.
pentobarbital will reduce the level or effect of lumacaftor/ivacaftor by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
Reserve concomitant prescribing of these drugs in people for whom other treatment method choices are inadequate. Restrict dosages and durations to the least necessary. Monitor closely for signs of respiratory depression and sedation.